BioMarin announced plans to discontinue preclinical studies in the BMN290 programme for Friedreich’s Ataxia

August 2019. BioMarin’s BMN 290 Programme: An Update for the Friedreich’s Ataxia Community On August 1, 2019 BioMarin announced plans to discontinue preclinical studies in the BMN290 programme for Friedreich’s Ataxia. BMN 290 is a selective chromatin modulationtherapy that has been under investigation as an active preclinical programme since 2017.All drug development companies actively manage their portfolios to ensure resources are directed as efficiently as possible. Despite a significant clinical research effort in Friedreich’s Ataxia, other research programmes within BioMarin continue to demonstrate a clearer path forward. It is with great regret that we are unable to pursue this programme further.

Henry Fuchs -- Executive Vice President and Chief Medical Officer: After my preclinical research and testing, we have determined this in the best interest of our R&D organization to put our resources toward products that have demonstrated a clear path forward. To take decisions very seriously, we will continue to take a disciplined approach when determining which portfolio assets align with our stage of growth and in the best interest of our shareholders and patients.



Biomarin Pharmaceutical Inc (BMRN) Q2 2019 Earnings Call Transcript